Dyne Therapeutics Inc
DYN20.140USD
+0.290+1.46%
Market hours （ET）Quotes delayed by 15 min
2.87BMarket Cap
LossP/E TTM
More Details of Dyne Therapeutics Inc Company
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Dyne Therapeutics Inc Info
Ticker SymbolDYN
Company nameDyne Therapeutics Inc
IPO dateSep 17, 2020
CEOCox (John)
Number of employees191
Security typeOrdinary Share
Fiscal year-endSep 17
Address1560 Trapelo Road
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone17817868230
Websitehttps://dyne-tx.com/
Ticker SymbolDYN
IPO dateSep 17, 2020
CEOCox (John)
Company Executives of Dyne Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.66K
-2.79%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Carlo Incerti, M.D.
Dr. Carlo Incerti, M.D.
Independent Director
Independent Director
--
--
Mr. Dirk Kersten
Mr. Dirk Kersten
Independent Director
Independent Director
--
--
Dr. Doug Kerr
Dr. Doug Kerr
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jason Rhodes
Mr. Jason Rhodes
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.66K
-2.79%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
9.13%
The Vanguard Group, Inc.
6.03%
Atlas Venture
5.65%
BlackRock Institutional Trust Company, N.A.
4.96%
Forbion Capital Partners
3.38%
Other
70.86%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
9.13%
The Vanguard Group, Inc.
6.03%
Atlas Venture
5.65%
BlackRock Institutional Trust Company, N.A.
4.96%
Forbion Capital Partners
3.38%
Other
70.86%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.58%
Investment Advisor/Hedge Fund
28.43%
Hedge Fund
18.40%
Venture Capital
14.11%
Private Equity
3.45%
Research Firm
2.55%
Individual Investor
0.52%
Pension Fund
0.34%
Foundation
0.32%
Other
1.31%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
448
158.30M
107.46%
+27.45K
2025Q3
454
158.31M
108.39%
+22.59M
2025Q2
434
130.55M
101.97%
+5.93M
2025Q1
429
124.85M
105.00%
+6.07M
2024Q4
402
113.11M
119.02%
-398.28K
2024Q3
386
113.48M
117.07%
+1.31M
2024Q2
363
112.24M
104.57%
+15.20M
2024Q1
314
96.67M
85.15%
+22.52M
2023Q4
273
71.44M
122.70%
+4.09M
2023Q3
258
67.27M
109.24%
+1.03M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
14.39M
10.12%
+4.96M
+52.52%
Jul 31, 2025
The Vanguard Group, Inc.
7.64M
5.37%
+244.81K
+3.31%
Jun 30, 2025
Atlas Venture
9.13M
6.42%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.59M
4.63%
+326.76K
+5.22%
Jun 30, 2025
Forbion Capital Partners
5.46M
3.84%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.29M
3.72%
+98.08K
+1.89%
Jun 30, 2025
State Street Investment Management (US)
3.36M
2.36%
-253.97K
-7.04%
Jun 30, 2025
Invus Public Equities Advisors, LLC
4.84M
3.4%
+2.12M
+77.94%
Jun 30, 2025
TCG Crossover Management, LLC
3.77M
2.65%
+1.12M
+42.13%
Jun 30, 2025
Adage Capital Management, L.P.
3.19M
2.24%
+3.19M
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
4.03%
State Street SPDR S&P Biotech ETF
1.18%
Virtus LifeSci Biotech Clinical Trials ETF
1.06%
JPMorgan Healthcare Leaders ETF
0.73%
Direxion Daily S&P Biotech Bull 3X Shares
0.72%
ProShares Ultra Nasdaq Biotechnology
0.38%
JPMorgan Fundamental Data Science Small Core ETF
0.35%
Optimize Strategy Index ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.31%
iShares Health Innovation Active ETF
0.29%
View more
iShares Neuroscience and Healthcare ETF
Proportion4.03%
State Street SPDR S&P Biotech ETF
Proportion1.18%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.06%
JPMorgan Healthcare Leaders ETF
Proportion0.73%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.72%
ProShares Ultra Nasdaq Biotechnology
Proportion0.38%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.35%
Optimize Strategy Index ETF
Proportion0.35%
Invesco Nasdaq Biotechnology ETF
Proportion0.31%
iShares Health Innovation Active ETF
Proportion0.29%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Dyne Therapeutics Inc?
The top five shareholders of Dyne Therapeutics Inc are:
Janus Henderson Investors holds 14.39M shares, accounting for 10.12% of the total shares.
The Vanguard Group, Inc. holds 7.64M shares, accounting for 5.37% of the total shares.
Atlas Venture holds 9.13M shares, accounting for 6.42% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.59M shares, accounting for 4.63% of the total shares.
Forbion Capital Partners holds 5.46M shares, accounting for 3.84% of the total shares.
Janus Henderson Investors holds 14.39M shares, accounting for 10.12% of the total shares.
The Vanguard Group, Inc. holds 7.64M shares, accounting for 5.37% of the total shares.
Atlas Venture holds 9.13M shares, accounting for 6.42% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.59M shares, accounting for 4.63% of the total shares.
Forbion Capital Partners holds 5.46M shares, accounting for 3.84% of the total shares.
What are the top three shareholder types of Dyne Therapeutics Inc?
The top three shareholder types of Dyne Therapeutics Inc are:
Janus Henderson Investors
The Vanguard Group, Inc.
Atlas Venture
Janus Henderson Investors
The Vanguard Group, Inc.
Atlas Venture
How many institutions hold shares of Dyne Therapeutics Inc (DYN)?
As of 2025Q4, 448 institutions hold shares of Dyne Therapeutics Inc, with a combined market value of approximately 158.30M, accounting for 107.46% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.92%.
What is the biggest source of revenue for Dyne Therapeutics Inc?
In --, the -- business generated the highest revenue for Dyne Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
